[
  {
    "ts": "2025-11-10T09:17:25+00:00",
    "headline": "Norway wealth fund abstains from Novo board vote; Stock up on dropped Metsera bid",
    "summary": "Investing.com -- Norway’s sovereign wealth fund said on Monday it will abstain from voting on new board members, including the chair, at Novo Nordisk’s extraordinary shareholders’ meeting on November 14.",
    "url": "https://finance.yahoo.com/news/norway-wealth-fund-abstains-novo-091725443.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "38f4b3ac-86d6-30c7-9b70-1e01d9424752",
      "content": {
        "id": "38f4b3ac-86d6-30c7-9b70-1e01d9424752",
        "contentType": "STORY",
        "title": "Norway wealth fund abstains from Novo board vote; Stock up on dropped Metsera bid",
        "description": "",
        "summary": "Investing.com -- Norway’s sovereign wealth fund said on Monday it will abstain from voting on new board members, including the chair, at Novo Nordisk’s extraordinary shareholders’ meeting on November 14.",
        "pubDate": "2025-11-10T09:17:25Z",
        "displayTime": "2025-11-10T09:17:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/norway-wealth-fund-abstains-novo-091725443.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/norway-wealth-fund-abstains-novo-091725443.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T10:05:43+00:00",
    "headline": "Pfizer to Acquire Metsera Under Amended Deal; Novo Nordisk Says No Plan to Increase Offer for Metsera",
    "summary": "Metsera (MTSR) said late Friday it signed an amended merger agreement with Pfizer (PFE) under which",
    "url": "https://finance.yahoo.com/news/pfizer-acquire-metsera-under-amended-100543786.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "c2d6ce71-d9bd-3bf0-93f0-b2a19433e5e1",
      "content": {
        "id": "c2d6ce71-d9bd-3bf0-93f0-b2a19433e5e1",
        "contentType": "STORY",
        "title": "Pfizer to Acquire Metsera Under Amended Deal; Novo Nordisk Says No Plan to Increase Offer for Metsera",
        "description": "",
        "summary": "Metsera (MTSR) said late Friday it signed an amended merger agreement with Pfizer (PFE) under which",
        "pubDate": "2025-11-10T10:05:43Z",
        "displayTime": "2025-11-10T10:05:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-acquire-metsera-under-amended-100543786.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-acquire-metsera-under-amended-100543786.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T09:38:00+00:00",
    "headline": "Novo Nordisk Shares Rise After Withdrawal from Metsera Takeover Battle",
    "summary": "Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal that could be worth more than $10 billion following a heated takeover battle.",
    "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-rise-after-withdrawal-from-metsera-takeover-battle-89b46614?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "d5b47e8a-d903-348e-98e6-497e6f129b68",
      "content": {
        "id": "d5b47e8a-d903-348e-98e6-497e6f129b68",
        "contentType": "STORY",
        "title": "Novo Nordisk Shares Rise After Withdrawal from Metsera Takeover Battle",
        "description": "",
        "summary": "Shares climbed as much as 3.5% in early European trade after Pfizer agreed to buy Metsera in a deal that could be worth more than $10 billion following a heated takeover battle.",
        "pubDate": "2025-11-10T09:38:00Z",
        "displayTime": "2025-11-10T09:38:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/d5b47e8a-d903-348e-98e6-497e6f129b68/novo-nordisk-shares-rise.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/2372424f5139c905c960e20b3b91cc99",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3RezSUeM_tSmgS.4CLrL0g--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/2372424f5139c905c960e20b3b91cc99.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dkixDZf9CkcNbqHexcQcRw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/2372424f5139c905c960e20b3b91cc99.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/novo-nordisk-shares-rise-after-withdrawal-from-metsera-takeover-battle-89b46614?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T09:18:45+00:00",
    "headline": "Novo Rises After Bowing Out of Metsera Takeover Battle",
    "summary": "Novo, the maker of Wegovy and Ozempic, decided to drop out of the running for Metsera on Saturday morning after Pfizer matched its latest offer in a bidding war that had pushed the price to levels that caused concern the bidders might be overpaying.  Adding to Novo’s obstacles, Metsera said it got a call from the US Federal Trade Commission flagging potential regulatory risks with the proposed Novo deal structure.  Pfizer agreed to pay $65.60 a share in cash for Metsera, as well as up to $20.65 a share contingent on certain milestones.",
    "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "8ceadc74-594e-32d2-a64a-0aea1a5b22f7",
      "content": {
        "id": "8ceadc74-594e-32d2-a64a-0aea1a5b22f7",
        "contentType": "STORY",
        "title": "Novo Rises After Bowing Out of Metsera Takeover Battle",
        "description": "",
        "summary": "Novo, the maker of Wegovy and Ozempic, decided to drop out of the running for Metsera on Saturday morning after Pfizer matched its latest offer in a bidding war that had pushed the price to levels that caused concern the bidders might be overpaying.  Adding to Novo’s obstacles, Metsera said it got a call from the US Federal Trade Commission flagging potential regulatory risks with the proposed Novo deal structure.  Pfizer agreed to pay $65.60 a share in cash for Metsera, as well as up to $20.65 a share contingent on certain milestones.",
        "pubDate": "2025-11-10T09:18:45Z",
        "displayTime": "2025-11-10T09:18:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3",
          "originalWidth": 2000,
          "originalHeight": 1334,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fmXrJtbI3H5zCMXkv.hLZw--~B/aD0xMzM0O3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3.cf.webp",
              "width": 2000,
              "height": 1334,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2i3MlmOJYQDWFClE3QXhFg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T10:45:00+00:00",
    "headline": "These Stocks Are Moving the Most Today: Metsera, Pfizer, Nvidia, Tesla, Rumble, CoreWeave, and More",
    "summary": "Metsera stock plunges after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 billion.",
    "url": "https://www.barrons.com/articles/stock-movers-dc8f3538?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "155d3d60-726a-3ca2-8f7c-3c18fd66640c",
      "content": {
        "id": "155d3d60-726a-3ca2-8f7c-3c18fd66640c",
        "contentType": "STORY",
        "title": "These Stocks Are Moving the Most Today: Metsera, Pfizer, Nvidia, Tesla, Rumble, CoreWeave, and More",
        "description": "",
        "summary": "Metsera stock plunges after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 billion.",
        "pubDate": "2025-11-10T10:45:00Z",
        "displayTime": "2025-11-10T10:45:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/155d3d60-726a-3ca2-8f7c-3c18fd66640c/these-stocks-are-moving-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/f6c2e51efdaee0a38422551ff9352718",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ev5Hki_Fwvy8oQ_mdjqQBQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/f6c2e51efdaee0a38422551ff9352718.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CgRBHKcdvBB.Vg_3MymuDA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/f6c2e51efdaee0a38422551ff9352718.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-dc8f3538?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "RUM"
            },
            {
              "symbol": "CRWV"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T13:08:23+00:00",
    "headline": "Pfizer clinches $10bn Metsera deal as Novo Nordisk retreats",
    "summary": "Pfizer’s US antitrust law play appears to have won the day, with Metsera choosing the less risky offer.",
    "url": "https://www.pharmaceutical-technology.com/news/pfizer-clinches-10bn-metsera-deal-as-novo-nordisk-retreats/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "1c498665-8183-3df0-88e1-084129aca738",
      "content": {
        "id": "1c498665-8183-3df0-88e1-084129aca738",
        "contentType": "STORY",
        "title": "Pfizer clinches $10bn Metsera deal as Novo Nordisk retreats",
        "description": "",
        "summary": "Pfizer’s US antitrust law play appears to have won the day, with Metsera choosing the less risky offer.",
        "pubDate": "2025-11-10T13:08:23Z",
        "displayTime": "2025-11-10T13:08:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/8bf5b1150e6db893d8f3635c156e3a76",
          "originalWidth": 1024,
          "originalHeight": 683,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_qGsCoQPq.iwzZ2o7.DW6w--~B/aD02ODM7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/8bf5b1150e6db893d8f3635c156e3a76.cf.webp",
              "width": 1024,
              "height": 683,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y4mwwFd6t8W3xpM7xjCc3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/8bf5b1150e6db893d8f3635c156e3a76.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/pfizer-clinches-10bn-metsera-deal-as-novo-nordisk-retreats/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-clinches-10bn-metsera-deal-130823492.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T12:43:57+00:00",
    "headline": "Stocks to Watch Monday: Barrick Mining, Metsera, Rumble, Tyson Foods",
    "summary": "↘️ Centene (CNC), Molina Healthcare (MOH), Oscar Health (OSCR): President Trump said the \"hundreds of billions of dollars\" paid to health insurers under the Affordable Care Act should go directly to the public.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-10-2025/card/stocks-to-watch-monday-metsera-novo-nordisk-nvidia-tyson-foods-q5Dl4ODGmWfLrrD481Zi?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "613177ca-5916-3e85-bfc2-c2c9b0a58872",
      "content": {
        "id": "613177ca-5916-3e85-bfc2-c2c9b0a58872",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Barrick Mining, Metsera, Rumble, Tyson Foods",
        "description": "",
        "summary": "↘️ Centene (CNC), Molina Healthcare (MOH), Oscar Health (OSCR): President Trump said the \"hundreds of billions of dollars\" paid to health insurers under the Affordable Care Act should go directly to the public.",
        "pubDate": "2025-11-10T12:43:57Z",
        "displayTime": "2025-11-10T12:43:57Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/613177ca-5916-3e85-bfc2-c2c9b0a58872/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7272dbf1b75e6a9bb4345c97982cd494",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VKDPvX7s1yi.scNXK0JOYw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7272dbf1b75e6a9bb4345c97982cd494.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7AZPRGpxoSyjz5ZEtw_klQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7272dbf1b75e6a9bb4345c97982cd494.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-10-2025/card/stocks-to-watch-monday-metsera-novo-nordisk-nvidia-tyson-foods-q5Dl4ODGmWfLrrD481Zi?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "DEO"
            },
            {
              "symbol": "DGEAF"
            },
            {
              "symbol": "NDTAF"
            },
            {
              "symbol": "ABX.TO"
            },
            {
              "symbol": "TSN"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "QSR"
            },
            {
              "symbol": "CNC"
            },
            {
              "symbol": "MOH"
            },
            {
              "symbol": "OSCR"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "NB2.F"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T12:33:00+00:00",
    "headline": "These Stocks Are Moving the Most Today: Metsera, Pfizer, Nvidia, Tesla, Rumble, Monday.com, CoreWeave, and More",
    "summary": "Metsera falls sharply after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 billion.",
    "url": "https://www.barrons.com/articles/stock-movers-dc8f3538?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "155d3d60-726a-3ca2-8f7c-3c18fd66640c",
      "content": {
        "id": "155d3d60-726a-3ca2-8f7c-3c18fd66640c",
        "contentType": "STORY",
        "title": "These Stocks Are Moving the Most Today: Metsera, Pfizer, Nvidia, Tesla, Rumble, Monday.com, CoreWeave, and More",
        "description": "",
        "summary": "Metsera falls sharply after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 billion.",
        "pubDate": "2025-11-10T12:33:00Z",
        "displayTime": "2025-11-10T12:33:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/155d3d60-726a-3ca2-8f7c-3c18fd66640c/these-stocks-are-moving-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/f6c2e51efdaee0a38422551ff9352718",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ev5Hki_Fwvy8oQ_mdjqQBQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/f6c2e51efdaee0a38422551ff9352718.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CgRBHKcdvBB.Vg_3MymuDA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/f6c2e51efdaee0a38422551ff9352718.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-dc8f3538?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "RUM"
            },
            {
              "symbol": "CRWV"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T12:32:00+00:00",
    "headline": "Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.",
    "summary": "The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.",
    "url": "https://www.barrons.com/articles/pfizer-stock-metsera-novo-nordisk-bid-b464be0a?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "71590089-0478-3897-bdd7-84cbe749cc78",
      "content": {
        "id": "71590089-0478-3897-bdd7-84cbe749cc78",
        "contentType": "STORY",
        "title": "Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.",
        "description": "",
        "summary": "The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.",
        "pubDate": "2025-11-10T12:32:00Z",
        "displayTime": "2025-11-10T12:32:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/71590089-0478-3897-bdd7-84cbe749cc78/pfizer-is-buying-weight-loss.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/37b47ecdd24a29c2bdecc18dc259eae9",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9_9AnN0zFgDTfb3AcpsDDw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/37b47ecdd24a29c2bdecc18dc259eae9.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zQTi3fgERMz4fAjnUUvpAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/37b47ecdd24a29c2bdecc18dc259eae9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/pfizer-stock-metsera-novo-nordisk-bid-b464be0a?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T12:00:00+00:00",
    "headline": "Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors",
    "summary": "Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertiseSAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previ",
    "url": "https://finance.yahoo.com/news/nurix-therapeutics-appoints-accomplished-biopharmaceutical-120000279.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "e2c74eca-5b4f-3e46-9400-ff86df8682dd",
      "content": {
        "id": "e2c74eca-5b4f-3e46-9400-ff86df8682dd",
        "contentType": "STORY",
        "title": "Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors",
        "description": "",
        "summary": "Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertiseSAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune diseases, today announced the appointment of Roger Dansey, M.D., to its board of directors. Dr. Dansey, who previ",
        "pubDate": "2025-11-10T12:00:00Z",
        "displayTime": "2025-11-10T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/2bac359058f8ba3c51bd304c2eb375c0",
          "originalWidth": 124,
          "originalHeight": 59,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bo1Kaht6Lnbt9HxUs8UQiw--~B/aD01OTt3PTEyNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/2bac359058f8ba3c51bd304c2eb375c0.cf.webp",
              "width": 124,
              "height": 59,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d4ApEsx4wkV_auIuBRdN4w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2bac359058f8ba3c51bd304c2eb375c0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nurix-therapeutics-appoints-accomplished-biopharmaceutical-120000279.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nurix-therapeutics-appoints-accomplished-biopharmaceutical-120000279.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NRIX"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T12:00:00+00:00",
    "headline": "Olema Oncology Reports Third Quarter 2025 Financial and Operating Results",
    "summary": "Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancerInitiated OPERA-02 Phase 3 trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancerPresented compelling new data from Phase 1b/2 study of palazestrant plus ribociclib at ESMO 2025Ended the quarter with $329.0 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWS",
    "url": "https://finance.yahoo.com/news/olema-oncology-reports-third-quarter-120000922.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "9d495d5c-956b-3676-a7e4-afe9b03e6bdc",
      "content": {
        "id": "9d495d5c-956b-3676-a7e4-afe9b03e6bdc",
        "contentType": "STORY",
        "title": "Olema Oncology Reports Third Quarter 2025 Financial and Operating Results",
        "description": "",
        "summary": "Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancerInitiated OPERA-02 Phase 3 trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancerPresented compelling new data from Phase 1b/2 study of palazestrant plus ribociclib at ESMO 2025Ended the quarter with $329.0 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWS",
        "pubDate": "2025-11-10T12:00:00Z",
        "displayTime": "2025-11-10T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/82f34ea0e328e54b1bb3d463e0ef2d0e",
          "originalWidth": 4168,
          "originalHeight": 1197,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/honwmojVcE9.ol.OqfFu6g--~B/aD0xMTk3O3c9NDE2ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/82f34ea0e328e54b1bb3d463e0ef2d0e.cf.webp",
              "width": 4168,
              "height": 1197,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qLxx0NFUNckBxxLcpnSn3A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/82f34ea0e328e54b1bb3d463e0ef2d0e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/olema-oncology-reports-third-quarter-120000922.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/olema-oncology-reports-third-quarter-120000922.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "OLMA"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T11:55:17+00:00",
    "headline": "Metsera Tumbles After Novo Pulls Out of Bidding War With Pfizer",
    "summary": "The shares slumped as much as 16% to $70.12 in US premarket trading.  The stock more than quadrupled from its January initial public offering through Friday’s close.  Novo, the maker of Wegovy and Ozempic, decided to drop out of the running for Metsera on Saturday after Pfizer matched its latest offer in a takeover battle that had caused concern the bidders might be overpaying for an unproven asset.",
    "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "8ceadc74-594e-32d2-a64a-0aea1a5b22f7",
      "content": {
        "id": "8ceadc74-594e-32d2-a64a-0aea1a5b22f7",
        "contentType": "STORY",
        "title": "Metsera Tumbles After Novo Pulls Out of Bidding War With Pfizer",
        "description": "",
        "summary": "The shares slumped as much as 16% to $70.12 in US premarket trading.  The stock more than quadrupled from its January initial public offering through Friday’s close.  Novo, the maker of Wegovy and Ozempic, decided to drop out of the running for Metsera on Saturday after Pfizer matched its latest offer in a takeover battle that had caused concern the bidders might be overpaying for an unproven asset.",
        "pubDate": "2025-11-10T11:55:17Z",
        "displayTime": "2025-11-10T11:55:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3",
          "originalWidth": 2000,
          "originalHeight": 1334,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fmXrJtbI3H5zCMXkv.hLZw--~B/aD0xMzM0O3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3.cf.webp",
              "width": 2000,
              "height": 1334,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2i3MlmOJYQDWFClE3QXhFg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/08c13e6140038c2411667c1d223dd9e3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-rises-bowing-metsera-takeover-091845437.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T14:33:06+00:00",
    "headline": "Pfizer & Metsera, Monday.com, Instacart: Trending Tickers",
    "summary": "Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Pfizer (PFE) outbidding Novo Nordisk (NVO) in its acquisition of Metsera (MTSR), monday.com (MNDY) shares diving nearly 20% in Monday's premarket after falling short of revenue forecast estimates, and Instacart (CART) — which operates as Maplebear, Inc. — beating its third quarter earnings estimates. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Morning Brief.",
    "url": "https://finance.yahoo.com/video/pfizer-metsera-monday-com-instacart-143306338.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "a410bd67-f0eb-3950-ba9b-5d4e5c5c79e4",
      "content": {
        "id": "a410bd67-f0eb-3950-ba9b-5d4e5c5c79e4",
        "contentType": "VIDEO",
        "title": "Pfizer & Metsera, Monday.com, Instacart: Trending Tickers",
        "description": "<p>Morning Brief host <a data-i13n=\"cpos:1;pos:1\" href=\"https://www.yahoo.com/author/julie-hyman/?.tsrc=fin-srch\">Julie Hyman</a> tracks several of the day's top trending stock tickers, including Pfizer (<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/PFE\">PFE</a>) outbidding Novo Nordisk (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/NVO\">NVO</a>) in its acquisition of Metsera (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/MTSR\">MTSR</a>), monday.com (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/MNDY\">MNDY</a>) shares diving nearly 20% in Monday's premarket after falling short of revenue forecast estimates, and Instacart (<a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/CART\">CART</a>) — which operates as Maplebear, Inc. — beating its third quarter earnings estimates.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/videos/series/morning-brief/\">Morning Brief</a>.</p>",
        "summary": "Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Pfizer (PFE) outbidding Novo Nordisk (NVO) in its acquisition of Metsera (MTSR), monday.com (MNDY) shares diving nearly 20% in Monday's premarket after falling short of revenue forecast estimates, and Instacart (CART) — which operates as Maplebear, Inc. — beating its third quarter earnings estimates. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Morning Brief.",
        "pubDate": "2025-11-10T14:33:06Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/629ca4b0-be41-11f0-a7ff-4c0b6e07c83b",
          "originalWidth": 3510,
          "originalHeight": 1976,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LrbofhrvrYoteLnzSfis2g--~B/aD0xOTc2O3c9MzUxMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/629ca4b0-be41-11f0-a7ff-4c0b6e07c83b.cf.webp",
              "width": 3510,
              "height": 1976,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t6DEx6iXROy.ZW0I4sVTEA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/629ca4b0-be41-11f0-a7ff-4c0b6e07c83b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/pfizer-metsera-monday-com-instacart-143306338.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/pfizer-metsera-monday-com-instacart-143306338.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CART"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "MNDY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T14:14:50+00:00",
    "headline": "Investors Monitor Potential Breakthrough to End Government Shutdown, Driving Premarket Gains for US Equity Futures",
    "summary": "US equity futures were up ahead of Monday's opening bell as traders monitored a potential breakthrou",
    "url": "https://finance.yahoo.com/news/investors-monitor-potential-breakthrough-end-141450509.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "6e544903-9ab2-36db-b3ad-50dd7016c620",
      "content": {
        "id": "6e544903-9ab2-36db-b3ad-50dd7016c620",
        "contentType": "STORY",
        "title": "Investors Monitor Potential Breakthrough to End Government Shutdown, Driving Premarket Gains for US Equity Futures",
        "description": "",
        "summary": "US equity futures were up ahead of Monday's opening bell as traders monitored a potential breakthrou",
        "pubDate": "2025-11-10T14:14:50Z",
        "displayTime": "2025-11-10T14:14:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-monitor-potential-breakthrough-end-141450509.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-monitor-potential-breakthrough-end-141450509.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CL=F"
            },
            {
              "symbol": "THS"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T14:11:02+00:00",
    "headline": "Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More",
    "summary": "Pre-Market Stock Futures: The futures are trading higher as the new week begins, with most investors and traders relieved that last week has come to a close. Hopes that an end to the Government shutdown in Congress is driving the futures higher this morning. The same mantra that was chanted last week — AI/Bubble, stocks ... Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More",
    "url": "https://247wallst.com/investing/2025/11/10/here-are-mondays-top-wall-street-analyst-research-calls-advanced-micro-devices-alphabet-apple-eli-lilly-carmax-hubspot-and-more/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ace44efa-7347-3f6a-83c7-287f1c5763b0",
      "content": {
        "id": "ace44efa-7347-3f6a-83c7-287f1c5763b0",
        "contentType": "STORY",
        "title": "Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More",
        "description": "",
        "summary": "Pre-Market Stock Futures: The futures are trading higher as the new week begins, with most investors and traders relieved that last week has come to a close. Hopes that an end to the Government shutdown in Congress is driving the futures higher this morning. The same mantra that was chanted last week — AI/Bubble, stocks ... Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Alphabet, Apple, Eli Lilly, CarMax, HubSpot, and More",
        "pubDate": "2025-11-10T14:11:02Z",
        "displayTime": "2025-11-10T14:11:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/ffa12de664351d2add9abe9bb1d08bbf",
          "originalWidth": 1500,
          "originalHeight": 1004,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I1EwqSI1cnGzFGg5FTnRpw--~B/aD0xMDA0O3c9MTUwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/24_7_wall_st__718/ffa12de664351d2add9abe9bb1d08bbf.cf.webp",
              "width": 1500,
              "height": 1004,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/i_i69s68TERJ5ajC3v63sA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/ffa12de664351d2add9abe9bb1d08bbf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/11/10/here-are-mondays-top-wall-street-analyst-research-calls-advanced-micro-devices-alphabet-apple-eli-lilly-carmax-hubspot-and-more/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/monday-top-wall-street-analyst-141102621.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMCX"
            },
            {
              "symbol": "EXPE"
            },
            {
              "symbol": "PCTY"
            },
            {
              "symbol": "HUBS"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "RUN"
            },
            {
              "symbol": "TDC"
            },
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "JD"
            },
            {
              "symbol": "JDCMF"
            },
            {
              "symbol": "HAS"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "KMX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T13:50:34+00:00",
    "headline": "Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Hopes of Government Reopening",
    "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up nearly 1% and the actively",
    "url": "https://finance.yahoo.com/news/exchange-traded-funds-equity-futures-135034320.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "0a4a0542-9e12-3bc9-8580-e22cc097023a",
      "content": {
        "id": "0a4a0542-9e12-3bc9-8580-e22cc097023a",
        "contentType": "STORY",
        "title": "Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Hopes of Government Reopening",
        "description": "",
        "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up nearly 1% and the actively",
        "pubDate": "2025-11-10T13:50:34Z",
        "displayTime": "2025-11-10T13:50:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/exchange-traded-funds-equity-futures-135034320.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/exchange-traded-funds-equity-futures-135034320.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "QQQ"
            },
            {
              "symbol": "SPY"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "BITO"
            },
            {
              "symbol": "XLP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T13:11:17+00:00",
    "headline": "5 Things to Know Before the Stock Market Opens",
    "summary": "News of the day for Nov. 10, 2025",
    "url": "https://www.investopedia.com/5-things-to-know-before-the-stock-market-opens-november-10-2025-11846510",
    "source": "Investopedia",
    "provider": "yfinance",
    "raw": {
      "id": "e60641c1-fdb0-3e07-b73c-93938f11a0af",
      "content": {
        "id": "e60641c1-fdb0-3e07-b73c-93938f11a0af",
        "contentType": "STORY",
        "title": "5 Things to Know Before the Stock Market Opens",
        "description": "",
        "summary": "News of the day for Nov. 10, 2025",
        "pubDate": "2025-11-10T13:11:17Z",
        "displayTime": "2025-11-10T13:11:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/investopedia_245/f31c6a0a1110ab701592385dfe340fde",
          "originalWidth": 5195,
          "originalHeight": 3493,
          "caption": "Tim Graham / Getty Images Investors are keeping close tabs on developments in Washington D.C. amid hopes that lawmakers will pass measures needed to reopen the government in the coming days.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w0tKCWOrWYo2xh9kCMFuTg--~B/aD0zNDkzO3c9NTE5NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/investopedia_245/f31c6a0a1110ab701592385dfe340fde.cf.webp",
              "width": 5195,
              "height": 3493,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/84DpguA0CDvcnCe4vELurA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/investopedia_245/f31c6a0a1110ab701592385dfe340fde.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investopedia",
          "url": "https://www.investopedia.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investopedia.com/5-things-to-know-before-the-stock-market-opens-november-10-2025-11846510",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-things-know-stock-market-131117451.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRWV"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T12:47:00+00:00",
    "headline": "Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?",
    "summary": "With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?",
    "url": "https://finance.yahoo.com/news/does-trumps-mfn-policy-put-124700612.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "dcd3dc33-f4d6-38e2-8bf5-54a8b59c80c9",
      "content": {
        "id": "dcd3dc33-f4d6-38e2-8bf5-54a8b59c80c9",
        "contentType": "STORY",
        "title": "Does Trump's MFN Policy Put Pharma ETFs in the Crosshairs?",
        "description": "",
        "summary": "With Trump's MFN policy cutting U.S. drug prices, will Pharma ETFs such as IHE, heavily weighted toward Eli Lilly and Novo Nordisk, lose momentum?",
        "pubDate": "2025-11-10T12:47:00Z",
        "displayTime": "2025-11-10T12:47:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/45ce84955e50e6f6403d57bc7fc0152f",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BeJV9aiRXQ9b7W2pfzjOng--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45ce84955e50e6f6403d57bc7fc0152f.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trGbfDPxS46b7DPVw4Xb1g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45ce84955e50e6f6403d57bc7fc0152f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/does-trumps-mfn-policy-put-124700612.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/does-trumps-mfn-policy-put-124700612.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "IHE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "PPH"
            },
            {
              "symbol": "PJP"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T14:57:10+00:00",
    "headline": "Novo Nordisk shares rise on investor relief after it exits Metsera bid",
    "summary": "<body><p>STORY: Shares in Novo Nordisk rose on Monday (November 10).</p><p>Investors bought in after the Wegovy maker lost out to Pfizer in a $10 billion bidding war for U.S. biotech Metsera.</p><p>Market watchers saw its offer as too complex.</p><p>The Danish drugmaker has also come under more pressure over governance.</p><p>That after Norway's sovereign wealth fund said it would abstain when Novo shareholders vote this week on a new board.</p><p>Pfizer said late Friday it had secured a deal for obesity drug developer Metsera.</p><p>It was a setback for Novo as it tries to compete with rival Eli Lilly in the weight-loss drug market.</p><p>Novo had started the bidding war in late October with an unsolicited offer a month after Metsera and Pfizer agreed a deal.</p><p>The U.S. Federal Trade Commission told Novo and Metsera last week their proposed deal risked breaking U.S. antitrust laws.</p><p>Metsera cited the&nbsp;antitrust concerns in rejecting Novo's bid.</p><p>The Danish drugmaker confirmed Saturday it would withdraw from the race.</p><p>Novo's shares were up 2.6% by Monday afternoon.</p><p>The stock has lost more than 70% of its value since June last year.</p></body>",
    "url": "https://finance.yahoo.com/video/novo-nordisk-shares-rise-investor-145710432.html",
    "source": "Reuters Videos",
    "provider": "yfinance",
    "raw": {
      "id": "0d08c42a-f478-3dba-b97e-d4c89dc5f661",
      "content": {
        "id": "0d08c42a-f478-3dba-b97e-d4c89dc5f661",
        "contentType": "VIDEO",
        "title": "Novo Nordisk shares rise on investor relief after it exits Metsera bid",
        "description": "<title><body><p>STORY: Shares in Novo Nordisk rose on Monday (November 10).</p><p>Investors bought in after the Wegovy maker lost out to Pfizer in a $10 billion bidding war for U.S. biotech Metsera.</p><p>Market watchers saw its offer as too complex.</p><p>The Danish drugmaker has also come under more pressure over governance.</p><p>That after Norway's sovereign wealth fund said it would abstain when Novo shareholders vote this week on a new board.</p><p>Pfizer said late Friday it had secured a deal for obesity drug developer Metsera.</p><p>It was a setback for Novo as it tries to compete with rival Eli Lilly in the weight-loss drug market.</p><p>Novo had started the bidding war in late October with an unsolicited offer a month after Metsera and Pfizer agreed a deal.</p><p>The U.S. Federal Trade Commission told Novo and Metsera last week their proposed deal risked breaking U.S. antitrust laws.</p><p>Metsera cited the antitrust concerns in rejecting Novo's bid.</p><p>The Danish drugmaker confirmed Saturday it would withdraw from the race.</p><p>Novo's shares were up 2.6% by Monday afternoon.</p><p>The stock has lost more than 70% of its value since June last year.</p></body></title>",
        "summary": "<body><p>STORY: Shares in Novo Nordisk rose on Monday (November 10).</p><p>Investors bought in after the Wegovy maker lost out to Pfizer in a $10 billion bidding war for U.S. biotech Metsera.</p><p>Market watchers saw its offer as too complex.</p><p>The Danish drugmaker has also come under more pressure over governance.</p><p>That after Norway's sovereign wealth fund said it would abstain when Novo shareholders vote this week on a new board.</p><p>Pfizer said late Friday it had secured a deal for obesity drug developer Metsera.</p><p>It was a setback for Novo as it tries to compete with rival Eli Lilly in the weight-loss drug market.</p><p>Novo had started the bidding war in late October with an unsolicited offer a month after Metsera and Pfizer agreed a deal.</p><p>The U.S. Federal Trade Commission told Novo and Metsera last week their proposed deal risked breaking U.S. antitrust laws.</p><p>Metsera cited the&nbsp;antitrust concerns in rejecting Novo's bid.</p><p>The Danish drugmaker confirmed Saturday it would withdraw from the race.</p><p>Novo's shares were up 2.6% by Monday afternoon.</p><p>The stock has lost more than 70% of its value since June last year.</p></body>",
        "pubDate": "2025-11-10T14:57:10Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/uu/api/res/1.2/k9c.YFkH1LI5zVTp6l.YOQ--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/4f64d6aa-8f56-48c7-8fc4-7aabbc3b2a19/main/1280x720/36s53ms/match/image.jpg",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ze1FWapG1vA7T2MzPsLpHg--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/4f64d6aa-8f56-48c7-8fc4-7aabbc3b2a19/main/1280x720/36s53ms/match/image.jpg.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/viSduL.78ECVSmbXBpO4bw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/4f64d6aa-8f56-48c7-8fc4-7aabbc3b2a19/main/1280x720/36s53ms/match/image.jpg.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters Videos",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/novo-nordisk-shares-rise-investor-145710432.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/novo-nordisk-shares-rise-investor-145710432.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T14:52:01+00:00",
    "headline": "Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion",
    "summary": "Metsera stock toppled Monday after the buyout battle with Pfizer and Novo Nordisk ended. Pfizer will acquire Metsera for up to $10 billion.",
    "url": "https://www.investors.com/news/technology/metsera-stock-pfizer-novo-nordisk-buyout-battle/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "a6dc4940-f6fd-35cc-9e75-bac8f369ab1d",
      "content": {
        "id": "a6dc4940-f6fd-35cc-9e75-bac8f369ab1d",
        "contentType": "STORY",
        "title": "Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion",
        "description": "",
        "summary": "Metsera stock toppled Monday after the buyout battle with Pfizer and Novo Nordisk ended. Pfizer will acquire Metsera for up to $10 billion.",
        "pubDate": "2025-11-10T14:52:01Z",
        "displayTime": "2025-11-10T14:52:01Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/a6dc4940-f6fd-35cc-9e75-bac8f369ab1d/metsera-tumbles-after-the.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/87f11d12863c52f96c96e06b559f0938",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZFzEDGzi9.wRZUw4Y5PFSQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/87f11d12863c52f96c96e06b559f0938.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/p0XFFO5brXbqYORX2gL7jQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/87f11d12863c52f96c96e06b559f0938.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/metsera-stock-pfizer-novo-nordisk-buyout-battle/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T14:43:33+00:00",
    "headline": "Stocks to Watch Monday: Barrick Mining, TSMC, Metsera, Tyson Foods",
    "summary": "↗️ TSMC (TSM, TW:2330): The contract chip maker's sales rose last month at the slowest pace since February 2024, but remained in double-digits. U.S.-listed American depositary receipts rose about 3%, part of a broader rebound in technology stocks.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-10-2025/card/stocks-to-watch-monday-metsera-novo-nordisk-nvidia-tyson-foods-q5Dl4ODGmWfLrrD481Zi?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "613177ca-5916-3e85-bfc2-c2c9b0a58872",
      "content": {
        "id": "613177ca-5916-3e85-bfc2-c2c9b0a58872",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Barrick Mining, TSMC, Metsera, Tyson Foods",
        "description": "",
        "summary": "↗️ TSMC (TSM, TW:2330): The contract chip maker's sales rose last month at the slowest pace since February 2024, but remained in double-digits. U.S.-listed American depositary receipts rose about 3%, part of a broader rebound in technology stocks.",
        "pubDate": "2025-11-10T14:43:33Z",
        "displayTime": "2025-11-10T14:43:33Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/613177ca-5916-3e85-bfc2-c2c9b0a58872/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7272dbf1b75e6a9bb4345c97982cd494",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VKDPvX7s1yi.scNXK0JOYw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7272dbf1b75e6a9bb4345c97982cd494.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7AZPRGpxoSyjz5ZEtw_klQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7272dbf1b75e6a9bb4345c97982cd494.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-10-2025/card/stocks-to-watch-monday-metsera-novo-nordisk-nvidia-tyson-foods-q5Dl4ODGmWfLrrD481Zi?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "TSM"
            },
            {
              "symbol": "TSMWF"
            },
            {
              "symbol": "RUMBW"
            },
            {
              "symbol": "NDTAF"
            },
            {
              "symbol": "B"
            },
            {
              "symbol": "2330.TW"
            },
            {
              "symbol": "ABX.TO"
            },
            {
              "symbol": "TSN"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NB2.F"
            },
            {
              "symbol": "RUM"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T14:25:20+00:00",
    "headline": "Pfizer Wins Obesity Drug Prize, With Trump Administration Assist",
    "summary": "Late Friday, after a dramatic bidding war, he learned he’d finally claimed his prize.  Bourla found out at around 9 p.m. that evening, according to people familiar with the matter, that the board of Metsera Inc., a three-year-old biotech startup developing a new generation of weight-loss drugs, had voted unanimously to accept Pfizer’s takeover offer of as much as $10 billion.  It was the climax of a Wall Street duel that had pitted Pfizer against the Danish pharmaceutical giant Novo Nordisk A/S – and a deal that is poised to set the global drug industry’s pecking order for years to come.",
    "url": "https://finance.yahoo.com/news/pfizer-wins-obesity-drug-prize-142520909.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "e7910f4e-43be-389a-bd78-19333b7fc6e5",
      "content": {
        "id": "e7910f4e-43be-389a-bd78-19333b7fc6e5",
        "contentType": "STORY",
        "title": "Pfizer Wins Obesity Drug Prize, With Trump Administration Assist",
        "description": "",
        "summary": "Late Friday, after a dramatic bidding war, he learned he’d finally claimed his prize.  Bourla found out at around 9 p.m. that evening, according to people familiar with the matter, that the board of Metsera Inc., a three-year-old biotech startup developing a new generation of weight-loss drugs, had voted unanimously to accept Pfizer’s takeover offer of as much as $10 billion.  It was the climax of a Wall Street duel that had pitted Pfizer against the Danish pharmaceutical giant Novo Nordisk A/S – and a deal that is poised to set the global drug industry’s pecking order for years to come.",
        "pubDate": "2025-11-10T14:25:20Z",
        "displayTime": "2025-11-10T14:25:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/0c16686f56eafb2a33ddabc50037e383",
          "originalWidth": 2000,
          "originalHeight": 1334,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KbU8W8WqXenHDms2P.X6dA--~B/aD0xMzM0O3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/0c16686f56eafb2a33ddabc50037e383.cf.webp",
              "width": 2000,
              "height": 1334,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nNQlrGGbU1WI1k3ncuVuiQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/0c16686f56eafb2a33ddabc50037e383.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-wins-obesity-drug-prize-142520909.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-wins-obesity-drug-prize-142520909.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T14:00:03+00:00",
    "headline": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-attracting-investor-140003637.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "308d3878-f162-3d44-8622-78195afd0809",
      "content": {
        "id": "308d3878-f162-3d44-8622-78195afd0809",
        "contentType": "STORY",
        "title": "Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know",
        "description": "",
        "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
        "pubDate": "2025-11-10T14:00:03Z",
        "displayTime": "2025-11-10T14:00:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2",
          "originalWidth": 900,
          "originalHeight": 741,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EYdBVn9rFNc9AepqcsmXXg--~B/aD03NDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2.cf.webp",
              "width": 900,
              "height": 741,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UC8YVzs0fyygH41RFBV7Qg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-attracting-investor-140003637.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-attracting-investor-140003637.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T13:54:00+00:00",
    "headline": "Bristol Myers Gains 7.2% in a Month:  Buy, Sell or Hold the Stock?",
    "summary": "Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.",
    "url": "https://finance.yahoo.com/news/bristol-myers-gains-7-2-135400428.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "6ef2afa4-42dc-373e-ace9-01f0c0da1376",
      "content": {
        "id": "6ef2afa4-42dc-373e-ace9-01f0c0da1376",
        "contentType": "STORY",
        "title": "Bristol Myers Gains 7.2% in a Month:  Buy, Sell or Hold the Stock?",
        "description": "",
        "summary": "Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.",
        "pubDate": "2025-11-10T13:54:00Z",
        "displayTime": "2025-11-10T13:54:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AZ1NFKr1Arip4UWINeWStw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zL5_evNVQm1N5N.bc6WldQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-gains-7-2-135400428.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-gains-7-2-135400428.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T13:33:00+00:00",
    "headline": "Pfizer Wins Battle for Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.",
    "summary": "The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.",
    "url": "https://www.barrons.com/articles/metsera-stock-price-pfizer-deal-novo-b464be0a?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "71590089-0478-3897-bdd7-84cbe749cc78",
      "content": {
        "id": "71590089-0478-3897-bdd7-84cbe749cc78",
        "contentType": "STORY",
        "title": "Pfizer Wins Battle for Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Real Winner.",
        "description": "",
        "summary": "The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.",
        "pubDate": "2025-11-10T13:33:00Z",
        "displayTime": "2025-11-10T13:33:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/71590089-0478-3897-bdd7-84cbe749cc78/pfizer-wins-battle-for.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/37b47ecdd24a29c2bdecc18dc259eae9",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9_9AnN0zFgDTfb3AcpsDDw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/37b47ecdd24a29c2bdecc18dc259eae9.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zQTi3fgERMz4fAjnUUvpAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/37b47ecdd24a29c2bdecc18dc259eae9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/metsera-stock-price-pfizer-deal-novo-b464be0a?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]